We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris
Read MoreHide Full Article
Bausch Health Companies Inc. (BHC - Free Report) announced that its division, Ortho Dermatologics, obtained the FDA approval for Altreno (tretinoin 0.05%) lotion, for the topical treatment of acne vulgaris in patients 9 years of age and older.
Per the company, Altreno is the first formulation of tretinoin in a lotion.
We note that Bausch started restructuring its dermatology business in 2017 by taking a number of actions, which included rebranding of the business, recruiting a new experienced leadership team, investing in the pipeline, adjusting the size of the dermatology sales force and reorganizing that sales force in roughly 150 territories. In July 2017, the dermatology business was rebranded as Ortho Dermatologics with a portfolio of several leading acne, anti-fungal and anti-infective products.
The new leadership is making efforts to further advance its portfolio. Siliq was launched in July 2017. Siliq is approved for the treatment of moderate-to-severe plaque psoriasis in adult patients, who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
Valeant entered into a collaboration agreement with AstraZeneca plc (AZN - Free Report) , granting the former an exclusive license to develop and commercialize Siliq globally, except in Japan and certain other Asian countries where the rights are held by Kyowa Hakko Kirin Co., Ltd. The agreement was amended in July 2016 to entitle Valeant the right to develop and commercialize Siliq in Europe.
However, the division suffered a setback when the FDA issued a complete response letter to its new drug application (NDA) for Duobrii, the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene for the treatment of moderate-to-severe plaque psoriasis in adults. The CRL did not specify any deficiencies related to the clinical efficacy or safety of Duobrii (provisional name) and did not identify issues with the company’s Chemistry, Manufacturing and Controls processes. The letter only noted questions regarding pharmacokinetic data.
Bausch plans to resubmit the NDA with the additional data during the third quarter and expects that the resubmission will be a Class II filing, which is usually a six-month review cycle.
Bausch narrowed its focus on seven recently launched products or expected to be launched in the near future, pending completion of testing and receiving FDA approval. The products include Vyzulta, Siliq, Bryhali (psoriasis), Lumify, Duobrii, Relistor and SiHy Daily.
Bausch’s stock has gained 13% in the year so far compared with growth of 5.3% for the industry.
After a tumultuous period, Bausch started a rebuilding process. The company recently changed its name as well. Even though it is still early to comment on the rebuilding process, the company in making efforts to sell non-core assets and pay down huge levels of debt. However, the dermatology market continues to be challenging.
Gilead’s earnings per share estimates have increased from $6.10 to $6.57 for 2018 in the last 60 days. Estimates for 2019 are also up by 14 cents.
Illumina’s earnings per share estimates have moved up from $4.87 to $5.46 for 2018 and from $5.61 to $6.17 for 2019 over the past 60 days.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris
Bausch Health Companies Inc. (BHC - Free Report) announced that its division, Ortho Dermatologics, obtained the FDA approval for Altreno (tretinoin 0.05%) lotion, for the topical treatment of acne vulgaris in patients 9 years of age and older.
Per the company, Altreno is the first formulation of tretinoin in a lotion.
We note that Bausch started restructuring its dermatology business in 2017 by taking a number of actions, which included rebranding of the business, recruiting a new experienced leadership team, investing in the pipeline, adjusting the size of the dermatology sales force and reorganizing that sales force in roughly 150 territories. In July 2017, the dermatology business was rebranded as Ortho Dermatologics with a portfolio of several leading acne, anti-fungal and anti-infective products.
The new leadership is making efforts to further advance its portfolio. Siliq was launched in July 2017. Siliq is approved for the treatment of moderate-to-severe plaque psoriasis in adult patients, who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
Valeant entered into a collaboration agreement with AstraZeneca plc (AZN - Free Report) , granting the former an exclusive license to develop and commercialize Siliq globally, except in Japan and certain other Asian countries where the rights are held by Kyowa Hakko Kirin Co., Ltd. The agreement was amended in July 2016 to entitle Valeant the right to develop and commercialize Siliq in Europe.
However, the division suffered a setback when the FDA issued a complete response letter to its new drug application (NDA) for Duobrii, the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene for the treatment of moderate-to-severe plaque psoriasis in adults. The CRL did not specify any deficiencies related to the clinical efficacy or safety of Duobrii (provisional name) and did not identify issues with the company’s Chemistry, Manufacturing and Controls processes. The letter only noted questions regarding pharmacokinetic data.
Bausch plans to resubmit the NDA with the additional data during the third quarter and expects that the resubmission will be a Class II filing, which is usually a six-month review cycle.
Bausch narrowed its focus on seven recently launched products or expected to be launched in the near future, pending completion of testing and receiving FDA approval. The products include Vyzulta, Siliq, Bryhali (psoriasis), Lumify, Duobrii, Relistor and SiHy Daily.
Bausch’s stock has gained 13% in the year so far compared with growth of 5.3% for the industry.
After a tumultuous period, Bausch started a rebuilding process. The company recently changed its name as well. Even though it is still early to comment on the rebuilding process, the company in making efforts to sell non-core assets and pay down huge levels of debt. However, the dermatology market continues to be challenging.
Zacks Rank & Key Pick
Bausch currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Gilead Sciences, Inc. (GILD - Free Report) and Illumina, Inc. (ILMN - Free Report) . Both the stocks carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead’s earnings per share estimates have increased from $6.10 to $6.57 for 2018 in the last 60 days. Estimates for 2019 are also up by 14 cents.
Illumina’s earnings per share estimates have moved up from $4.87 to $5.46 for 2018 and from $5.61 to $6.17 for 2019 over the past 60 days.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>